Experimental HIV Drugs
Experimental HIV Drugs
FDA Declines Approval of Elvitegravir and Cobicistat as Stand-alone HIV Meds
- Details
- Category: HIV Treatment
- Published on Tuesday, 07 May 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) has rejected approval of Gilead Sciences' integrase inhibitor elvitegravir and pharmacoenhancer cobicistat -- components of the 4-in-1 Stribild quad pill -- as single agents for treatment of HIV, the company announced last week.
CROI 2013: MK-1439 -- A Novel NNRTI For HIV Treatment [VIDEO]
- Details
- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated good antiretroviral activity and tolerability as 7-day monotherapy in a small Phase 1b trial, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Dolutegravir Helps Highly-resistant Treatment-experienced People on Failing ART
- Details
- Category: HIV Treatment
- Published on Friday, 08 March 2013 00:00
- Written by Liz Highleyman
The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for highly treatment-experienced people with resistance to 2 or more antiretroviral drug classes, researchers reported in a poster presented at the20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.
CROI 2013: Challenges and Opportunities for the Development of Long-acting Antiretrovirals [VIDEO]
- Details
- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
Marta Boffito from Chelsea and Westminster Hospital in London presented an overview of some of the challenges and opportunities in the development of long-acting antiretroviral agents for HIV treatment and prevention in a themed discussion at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: New Antiretroviral Agents: Cenicriviroc [VIDEO]
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Gregory Fowler
Tobira's cenicriviroc, a dual CCR5 and CCR2 receptor blocker with both antiviral and anti-inflammatory action, appears effective and better tolerated than some currently approved drugs, according to data presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
More Articles...
- CROI 2013: CCR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-inflammatory Effects
- CROI 2013: MK-1439, a Novel HIV NNRTI, Shows Promise in Early Clinical Trials
- CROI 2013: Pipeline Antiretrovirals Promise More Effective and Better Tolerated HIV Treatment
- CROI 2013: Development of Small Molecules for HIV Eradication [VIDEO]
Web Design and Development by